>Skipping clinical trials would be a major competitive advantage (lower costs, quicker to market etc.), but we don't allow that for the same reason About that

>Skipping clinical trials would be a major competitive advantage (lower costs, quicker to market etc.), but we don't allow that for the same reason About that ... Have you seen http://www.fdareview.org/05_harm.php http://www.fdareview.org/05_harm.php and http://www.fdareview.org/07_market_failure.php http://www.fdareview.org/07_market_failure.php?